Linerixibat
CAS 1345982-69-5Small Molecule
Overview
Linerixibat is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL2387408).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Linerixibat expires 6 Sept 2031 and exclusivity 17 Mar 2033. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid
- Canonical SMILES
- CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC
- InChIKey
- CZGVOBIGEBDYTP-VSGBNLITSA-N
Verified Supplier Partner
Do you supply Linerixibat? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.